DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-923

MAY 28 1998

Mallinckrodt Medical, Inc.
675 McDonnell Blvd.
St. Louis, MO 63134

Attention: Clarice Kassoff
Senior Regulatory Affairs Associate

Dear Ms. Kassoff:

Please refer to your new drug application dated September 30, 1997, received October 1, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Optiray Pharmacy Bulk Package, Ioversol Injection, 350 mg/mL, 320 mg/mL, and 240 mg/mL.

We acknowledge receipt of your submissions dated October 16, 1997, and March 27, 1998. The User Fee goal date for this application is October 1, 1998.

This new drug application provides for Pharmacy Bulk Packages of Optiray 240 mg, Optiray 320 mg, and Optiray 350 mg filled with 200 mL of solution in 250 mL bottles.

We have completed the review of this application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed marked-up draft labeling. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-923. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you of your Phase 4 commitments specified in your submission dated March 27, 1998. These commitments, along with any completion dates agreed upon, are listed below.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. Should an IND not be required to meet your Phase 4 commitments, please submit protocol, data, and final reports to this NDA as correspondence. In addition, we request under 21 CFR 314.81(b)(2)(vii) that you include in your annual report to this application, a status summary of each commitment. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications,
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Catalina Ferre-Hockensmith, Consumer Safety Officer, at (301) 443-3500.

Sincerely yours

Patricia Y. Love, M.D., M.B.A.
Director
Division of Medical Imaging and
Radiopharmaceutical Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE